Lupin’s Goa Facility Inspection Analyzed

Lupin, a major drug maker, recently had a check-up of its factory in Goa by the U.S. Food and Drug Administration (FDA). This inspection happened between November 10th and November 21st, 2025, and the FDA found seven things they wanted Lupin to fix. These findings were recorded as a “Form 483,” which is a standard way for the FDA to point out problems during inspections.

• FDA inspected Lupin’s Goa factory in November 2025.
• Seven observations were noted during the FDA inspection.
• Form 483 indicates areas needing improvement at Lupin.
• Lupin is committed to following strict drug-making rules.
• Lupin’s profits increased significantly in the last quarter.
• Lupin’s share price saw a slight decrease during the period.

About Lupin

Lupin is a large company that makes medicines for many countries. They create both well-known brands and cheaper versions of drugs. They also make the ingredients that go into many medications, and they even make some medicines themselves, including medicines that are very complicated to make. They sell their products in over 100 countries around the world, and are based in Mumbai, India.

Financial Performance

Lupin had a really good quarter. Their profits jumped by 73.33% to Rs 1,477.92 crore – that’s a big increase from the previous year. Their sales also went up by 24.27% to Rs 6,831.43 crore.

Despite the positive financial results, Lupin’s share price dipped slightly, ending at Rs 2,028.70 on the BSE.

“This inspection highlights the importance of continuous improvement and adherence to global standards within Lupin’s operations.”